medigraphic.com
Órgano de Difusión de la Asociación Académica Panamericana de Medicina Familiar A.C.

2007, Number 2

<< Back Next >>

Arch Med Fam 2007; 9 (2)

Pharmacosurveillance Program in Primary Care: The Experience at a Clinic in Veracruz, Mexico

Rascón-Sabido R, Sabido-Siglher AS, Márquez-Celedonio FG, Soler-Huerta E

Language: Spanish
References: 19
Page: 92-98
PDF size: 180.26 Kb.


ABSTRACT

Objective: To identify the main pharmaceuticals with suspicion of side effects, as well as the opinion of Family Physicians on the Pharmacosurveillance Program (PhSP). Materials and Methods: We conducted a descriptive and transversal study, registering cases of side effects reported by Family Physicians during 1 year by means of the Mexican Secretariat of Health (SSA)-03-021 format. At the end of the year, we applied a survey on knowledge and opinion regarding the PhSP to 25 Family Physicians at the Veracruz North Delegation’s Mexican Institute of Social Security’s (IMSS) No. 61 Family Medicine Unit. We utilized descriptive statistics in the analysis. Results: Sixty cases were reported with suspicion of side effects, including 37 females and 23 males. The pharmaceutical group with the highest number of reports comprised prescriptions for infectious and parasitic diseases, followed by medicaments for cardiologic and analgesic diseases. The surveys applied indicate that 16 Family Physicians were aware of the PhSP, but that these only referred a total of eight patients to control. The Physicians cited excessive work as the main obstacle for carrying out reports.Conclusions: We did not obtain the expected goals by means of the PhSP, which is in agreement with the international experience. The need exists to improve the culture of the medical report and to propose novel strategies to achieve goal compliance.


REFERENCES

  1. WHO.Collaborating Centre for International Drug Monitoring. Viewpoint part1.Upssala,Sweden:The Uppsala Monitoring Centre;2002.

  2. Rodríguez Betancourt L, García Vigil JL, Giral Valdez C, Santillan Hernández D, Gutiérrez Jasso L. Farmacovigilancia I El Inicio. Rev Med IMSS 2004;42(4):327-329.

  3. Rodríguez Betancourt L, García Vigil JL, Giral Valdez C, Santillan Hernandez D, Gutierrez Jasso. Farmocovilancia III. La experiencia Internacional. Rev Med IMSS 2005;43(2):131-140.

  4. Rodríguez Betancourt L, García Vigil JL, Giral Valdez C, Santillan Hernandez D, Gutierrez Jasso. Farmacovigilancia II. Las reacciones adversas de los medicamentos y el programa Internacional de Monitoreo de los Medicamentos. Rev Med IMSS 2004;42(5)419-423.

  5. Hernández-Santillan David L,Rodriuguez- Betancourt L,Jasso-Gutierrez L. Farmacovigilancia IV. La experiencia Institucional. Rev Med IMSS 2005;43(3): 257-266.

  6. Van Grootheest K, Olsson S, Couper M, de Jong-van den Berg L. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf. 2004 Jul;13(7):457-64.

  7. Ionescu SD, Sandru V, Leuciuc E, Manea P, Burdujan A, Tovarnitchi S, Cosovanu A. Undesirable effects and interaction to angiotensin converting enzyme inhibitors therapy. Rev Med Chir Soc Med Nat Iasi. 2002 Jan-Mar;106(1):128-31.

  8. Myers MG. Dihydropyridine calcium antagonists and the trough: peak ratio: focus on adverse effects.J Hypertens Suppl. 1994 Nov;12(8):S73-6; discussion S76-7.

  9. Green AG. Understanding NSAIDS: from aspirin to COX-2.Clin Cornestone 2001;3(5):50-59.

  10. Zochling J, Bohl-Buhler MH, Baraliakos X, Feldtkeller E, Braun J. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis-a population-based survey. Clin Rheumatol. 2006 Nov;25(6):794-800. Epub 2006 Mar.

  11. Ciccolunghi SN, Chaudri HA, Schubiger BI. The value and results of long-term studies with diclofenac sodium (Voltarol). Rheumatol Rehabil. 1979;Suppl 2:100-15.

  12. Abid S, Mumtaz K, Jafri W, Hamid S, Abbas Z, Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy. 2005 Aug;37(8):740-4.

  13. Mercado FA. Influencia de los cambios en el pH extracelular sobre las propiedades electrofisiológicas de las células aisladas del vestíbulo. Tesis, Benemérita Universidad Autónoma de Puebla, 2003).

  14. Fernandes PA, Pires MS, Gouvea AP. Ulcerative esophagitis associated with the use of alendronate sodium: histopathological and endoscopic features. Arq Gastroenterol. 2002 Jul-Sep;39(3):173-176.

  15. Luciani J, Pigatto V, Naves A, Fay M, Silvestre Begnis M. Esophagitis associated with use of alendronate in 5 postmenopausic patients. Acta Gastroenterol Latinoam. 2001 May;31(2):59-63

  16. Reacciones adversas. Revista Panamericana de Salud Pública Year: 1997 Vol: 2 Issue: 1 Pages/record No.: 67-70.

  17. Cosentino M, Leoni O, Banfi F, Lecchini S, Frigo G. Attitudes to adverse drug reaction reporting by medical practitioners in a Northern Italian district. Pharmacol Res. 1997;35(2):85-88.

  18. Tubert-Bitter P, Haramburu F, Begaud B, Chaslerie A, Abraham E, Hagry C. Spontaneous reporting of adverse drug reactions: who reports and what?. Pharmacoepidemiol Drug Saf. 1998 Sep;7(5):323-9.

  19. Van Grootheest AC, Passier JL, van Puijenbroek EP. Direct reporting of side effects by the patient: favourable experience in the first year; Ned Tijdschr Geneeskd. 2005 Mar 5;149(10):529-33.




2020     |     www.medigraphic.com